Symptomatic therapy and neurorehabilitation in multiple sclerosis (Q28272731)

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

Europe PubMed Central

title

Symptomatic therapy and neurorehabilitation in multiple sclerosis (English)

0 references

0 references

Jürg Kesselring

1

0 references

Serafin Beer

series ordinal

2

0 references

language of work or name

English

0 references

publication date

October 2005

0 references

published in

Lancet Neurology

0 references

volume

4

0 references

issue

10

0 references

page(s)

643-52

0 references

1 reference

7 January 2021

Disability, disease duration, and rehabilitation service needs in multiple sclerosis: patient perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Natural history of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Cognitive dysfunction in multiple sclerosis.: II. Impact on employment and social functioning

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Cost of multiple sclerosis by level of disability: a review of literature.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

An electrophysiological study of the mechanism of fatigue in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Quantification of Uhthoff's phenomenon in multiple sclerosis: a magnetic stimulation study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Increased endothelin-1 plasma levels in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Amantadine for fatigue in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Pelvic floor rehabilitation is effective in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Restorative Nursing Bladder Training program: recommending a strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Published evidence favors the use of suprapubic catheters in pelvic colorectal surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Botulinum toxin as a new therapy option for voiding disorders: current state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Urinary tract infection: traditional pharmacologic therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Phenazopyridine in urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Decreased incidence of urinary tract infections in patients with spinal cord injury: effect of methenamine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Sexual dysfunction in multiple sclerosis: a MRI, neurophysiological and urodynamic study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Side effects of chronic intrathecal baclofen on erection and ejaculation in patients with spinal cord lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Rehabilitation of intimacy and sexual dysfunction in couples with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

A multimodal approach to managing the symptoms of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Depression, cognitive impairment and social stress in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

A comprehensive assessment of the cost of multiple sclerosis in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Measures of physical and cognitive function and work status among individuals with multiple sclerosis: a review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Donepezil improved memory in multiple sclerosis in a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Computer assisted retraining of attentional impairments in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Depression associated with multiple sclerosis. Looking beyond diagnosis to symptom expression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Depression in multiple sclerosis as a function of length and severity of illness, age, remissions, and perceived social support

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Depression in multiple sclerosis: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Cognitive and affective disturbances in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Prevalence and treatment of spasticity reported by multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Treatment of spasticity with botulinum toxin: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Botulinum toxin A for spasticity, muscle spasms, and rigidity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

A summary of spasticity management--a treatment algorithm.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Value and application of the ICF in rehabilitation medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Adaptive functional changes in the cerebral cortex of patients with nondisabling multiple sclerosis correlate with the extent of brain structural damage

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Prospective study of neurorehabilitation in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

The impact of inpatient rehabilitation on progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Multiple sclerosis rehabilitation: inpatient vs. outpatient

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Impact of neurorehabilitation on disability in patients with acutely and chronically disabling diseases of the nervous system measured by the Extended Barthel Index

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Extended outpatient rehabilitation: its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Effects of a short outpatient rehabilitation treatment on disability of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Physical rehabilitation has a positive effect on disability in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Impact of aerobic training on fitness and quality of life in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

The effectiveness of physical, psychological, and functional interventions in treating clients with multiple sclerosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

[Deglutition disorders in neurological patients. A prospective study of diagnosis, pattern of impairment, therapy and outcome]

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

Respiratory muscle weakness and respiratory muscle training in severely disabled multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970193-9

7 January 2021

10.1016/S1474-4422(05)70193-9

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

release_mk347gkncbh6xaawtc25fnnqji

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mk347gkncbh6xaawtc25fnnqji

24 November 2022

mapped directly with Wikidata item

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

16168933

1 reference

Consolidated OpenCitations Corpus – April 2017